Abstract
Purpose
We evaluated the influence of preoperative treatments with biologics on surgical morbidity in patients with Crohn’s disease (CD).
Methods
We reviewed the surveillance data of patients with CD who underwent surgery between April 2018 and April 2021. The possible risk factors for morbidity were analyzed.
Results
A total of 305 surgically treated patients were included. Anti-TNF alpha agents and ustekinumab were used in 92 and 27 patients, respectively, within 12 weeks before surgery. There were no cases of mortality. In total, 70/305 (23.0%) patients developed a complication, and 42/305 (13.8%) patients developed a surgical site infection (SSI) (17 incisional SSIs and 35 organ/space SSIs). Current smoking status (OR 3.44), emergent/urgent surgery (OR 6.85), and abdominoperineal resection (APR) (OR 14.93) were identified as risk factors for total complications. Penetrating disease (OR 14.55) was identified as a risk factor for incisional SSIs. Current smoking status (OR 7.09), an American Society of Anesthesiologists (ASA) score greater than 3 (OR 5.85), a postoperative blood sugar level over 155 mg/dL (OR 4.37), and APR (OR 207.95) were identified as risk factors for organ/space SSIs.
Conclusions
No correlation between preoperative treatment with biologics and surgical mortality or morbidity was found. However, we should perform further analyses on a larger number of patients because the analyses may be limited by selection bias for treatment and several confounding factors.
Similar content being viewed by others
References
Van Assche G, Rutgeerts P (2000) Anti-TNF agents in Crohn’s disease. Expert Opin Investig Drugs 9:103–111
Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549
Stidham RW, Lee TC, Higgins PD et al (2014) Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther 39:1349–1362
Xu Y, Yang L, An P et al (2019) Meta-analysis: the influence of preoperative infliximab use on postoperative complications of Crohn’s disease. Inflamm Bowel Dis 25:261–269
Lin YS, Cheng SW, Wang YH et al (2019) Systematic review with meta-analysis: risk of post-operative complications associated with pre-operative exposure to anti-tumor necrosis factor agents for Crohn’s disease. Aliment Pharmacol Ther 49:966–977
Adamina M, Bonovas S, Raine T et al (2020) ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment. J Crohns Colitis 14:155–168
Lightner AL, McKenna NP, Tse CS et al (2018) Postoperative outcomes in ustekinumab-treated patients undergoing abdominal operations for Crohn’s disease. J Crohns Colitis 12:402–407
Shim HH, Ma C, Kotze PG et al (2018) Preoperative ustekinumab treatment is not associated with increased postoperative complications in Crohn’s disease: a Canadian multi-centre observational cohort study. J Can Assoc Gastroenterol 1:115–123
Garg R, Mohan BP, Ponnada S et al (2021) Postoperative outcomes after preoperative ustekinumab exposure in patients with Crohn’s disease: a systematic review and meta-analysis. Ann Gastroenterol 34:691–698
García MJ, Rivero M, Miranda-Bautista J et al (2021) Impact of biological agents on postsurgical complications in inflammatory bowel disease: a multicentre study of Geteccu. J Clin Med 10:4402
Smith RL, Bohl JK, McElearney ST et al (2004) Wound infection after elective colorectal resection. Ann Surg 239:599–607
Louis E, Collard A, Oger AF et al (2001) Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49:777–782
Uchino M, Ikeuchi H, Bando T et al (2019) Efficacy of preoperative oral antibiotic prophylaxis for the prevention of surgical site infections in patients with Crohn’s disease: a randomized controlled trial. Ann Surg 269:420–426
Dindo D, Demartines N et al (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213
Culver DH, Horan TC, Gaynes RP et al (1991) Surgical wound infection rates by wound class, operative procedure, and patient risk index. National Nosocomial Infections Surveillance System. Am J Med 91:152S-158S
Horan TC, Gaynes RP, Martone WJ et al (1992) CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 13:606–608
Narula N, Charleton D, Marshall JK (2013) Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease. Aliment Pharmacol Ther 37:1057–1064
Ganesh Kumar N, Khouri AN, Byrn JC et al (2021) The role of autologous flap reconstruction in patients with Crohn’s disease undergoing abdominoperineal resection. Dis Colon Rectum 64:429–437
Pędziwiatr M, Mavrikis J, Witowski J et al (2018) Current status of enhanced recovery after surgery (ERAS) protocol in gastrointestinal surgery. Med Oncol 35:95
Global guidelines for the prevention of surgical site infection. http://apps.who.int/iris/bitstream/10665/250680/1/9789241549882-eng.pdf. Accessed 1 Dec 2016
Oshima T, Takesue Y, Ikeuchi H et al (2013) Preoperative oral antibiotics and intravenous antimicrobial prophylaxis reduce the incidence of surgical site infections in patients with ulcerative colitis undergoing IPAA. Dis Colon Rectum 56:1149–1155
Cornillie F, Shealy D, D’Haens G et al (2001) Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther 5:463–473
Author information
Authors and Affiliations
Contributions
Motoi Uchino, conception and design of the study, data analysis, and drafting of the article; Yuki Horio, Ryuichi Kuwahara, Tomohiro Minagawa, Kusunoki Kurando, Yoshiko Goto, Naohito Beppu, and Masataka Ikeda, data acquisition; Kazuhiko Nakajima, Kaoru Ichiki, and Takashi Ueda, SSI data acquisition (infection control team); Hiroki Ikeuchi and Masataka Ikeda, interpretation of the data and critical revision of the article.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Uchino, M., Ikeuchi, H., Horio, Y. et al. Association between preoperative biologic use and surgical morbidity in patients with Crohn’s disease. Int J Colorectal Dis 37, 999–1010 (2022). https://doi.org/10.1007/s00384-022-04140-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-022-04140-8